Williams Beuren Syndrome
Conditions
Keywords
Williams Beuren syndrome, Cardiovascular abnormalities, Cardiovascular structure
Brief summary
The Williams-Beuren syndrome (WBS) is a sporadic congenital disorder characterized by a multisystem developmental impairment. This syndrome is caused by a microdeletion in chromosome 7q11.23 that encompasses loss of the elastin locus. Elastin, which is part of the extracellular matrix, controls proliferation of vascular smooth muscle cells (VSMCs) and stabilizes arterial structure. Loss of elastin gene in WBS patients has been claimed to provide a biological basis for the abnormal elastic fibre properties leading to cardiovascular abnormalities like supravalvular aortic stenosis (SVAS), hypertension, arteriosclerosis and stenosis in more than 50% of WBS children. These cardiovascular pathologies result in important consequences and neither curative nor preventive medicinal treatments exist at this time. Surgery is needed in more than half cases, while it is often leading to complications. Minoxidil is a well-known antihypertensive drug used in adults and children. Furthermore, according to animal studies, minoxidil seems to increase arterial elastin content by decreasing elastase activity in these tissues. Other data demonstrate that minoxidil specifically stimulate elastin synthesis. Working Hypothesis:If insufficient elastin synthesis leads to vascular complications and arterial hypertension in children with WBS, restoration of sufficient quantity of elastin should then result in prevention or inhibition of vascular malformations and improvement in arterial tension. Therefore, as a pharmacological agent capable to stimulate elastin expression, minoxidil might be a useful drug for the treatment of abnormal elastin metabolism in WBS children. Objective:To evaluate the efficacy of minoxidil on cardiovascular structure in children with Williams Beuren syndrome. Methodology: randomized controlled trial on two parallel group (23 patients in each arm) Main criterion:variation of carotid Intima-media thickness (IMT) before and after 12 months of treatment with Minoxidil versus placebo Secondary intermediate criteria of the vascular properties are arterial stiffness, cardiac and renal stenosis, arterial tension. Total study duration:30 months including a 12 month-recruitment period
Interventions
DRUGMinoxidil
Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more. Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.
DRUGPlacebo
Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more. Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.
Sponsors
Hospices Civils de Lyon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* proven diagnosis of Williams Beuren syndrome (genetic test) * normotension or hypertension, treated or not * male or female, * 6\< age \<18, * negative pregnancy test for childbearing potential female * effective birth control for sexually active female * signed consent form collected from parents or legal guardian
Exclusion criteria
* pulmonary hypertension secondary to mitral stenosis * myocardial infarction within 1 month prior randomization * known allergies to minoxidil or any of the components of Lonoten. * asthma * renal failure (creatinine clearance \<40ml/min) * no affiliation to a national health insurance program (social security) * intolerance to lactose * current vasodilator anti hypertensive treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Variation of Carotid Intima-media Thickness (IMT) Assessed by Vascular Echography | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy of Minoxidil on Humeral IMT Assessed by Vascular Echography | 18 months |
| Efficacy of Minoxidil on Arterial Stiffness (Pulse Wave Velocity and Vascular Compliance at J0, M12 and M18) | 18 months |
| Efficacy of Minoxidil on Supravalvular Stenosis, Pulmonary Stenosis, Aortic Stenosis and Renal Stenosis (Cardiac and Renal Echodoppler at J0, and M12) | 12 months |
| Efficacy of Minoxidil on Arterial Tension (24H-Holter at J0 and M12) | 12 months |
| Effect of Minoxidil on Neurohumoral Mechanisms of Cardiovascular Regulation and on Plasmatic Markers of the Extracellular Matrix. | 12 months |
| Genetic Study: Characterization of Deletions Responsible for WBS (Size Deletion, DNA Sample at Inclusion). | Day 0 |
Countries
France
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Minoxidil Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.
Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.
Minoxidil: Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.
Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more. | 9 |
| Placebo Placebo = lactose
Placebo: Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.
Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more. | 12 |
| Total | 21 |
Baseline characteristics
| Characteristic | Minoxidil | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 12.33 years STANDARD_DEVIATION 4.42 | 10.75 years STANDARD_DEVIATION 3.77 | 11.43 years STANDARD_DEVIATION 4.03 |
| BMI | 17.93 Kg/cm2 STANDARD_DEVIATION 3.88 | 17.54 Kg/cm2 STANDARD_DEVIATION 3.3 | 17.71 Kg/cm2 STANDARD_DEVIATION 3.47 |
| Diastolic Blood Pressure | 78.22 mmHg STANDARD_DEVIATION 15.58 | 73.17 mmHg STANDARD_DEVIATION 8.97 | 75.33 mmHg STANDARD_DEVIATION 12.16 |
| History of cardiovascular disease | 4 Participants | 6 Participants | 10 Participants |
| History of hypertension | 2 Participants | 2 Participants | 4 Participants |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Sex: Female, Male Female | 5 Participants | 4 Participants | 9 Participants |
| Sex: Female, Male Male | 4 Participants | 8 Participants | 12 Participants |
| Systolic Blood Pressure | 128.11 mmHg STANDARD_DEVIATION 16.78 | 120.83 mmHg STANDARD_DEVIATION 12.68 | 123.95 mmHg STANDARD_DEVIATION 14.65 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 5 / 9 | 0 / 12 |
| serious Total, serious adverse events | 1 / 9 | 1 / 12 |
Outcome results
Primary
Variation of Carotid Intima-media Thickness (IMT) Assessed by Vascular Echography
Time frame: 12 months
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Minoxidil | Variation of Carotid Intima-media Thickness (IMT) Assessed by Vascular Echography | 0.028 mm |
| Placebo | Variation of Carotid Intima-media Thickness (IMT) Assessed by Vascular Echography | 0.012 mm |
Secondary
Effect of Minoxidil on Neurohumoral Mechanisms of Cardiovascular Regulation and on Plasmatic Markers of the Extracellular Matrix.
Time frame: 12 months
Secondary
Efficacy of Minoxidil on Arterial Stiffness (Pulse Wave Velocity and Vascular Compliance at J0, M12 and M18)
Time frame: 18 months
Secondary
Efficacy of Minoxidil on Arterial Tension (24H-Holter at J0 and M12)
Time frame: 12 months
Secondary
Efficacy of Minoxidil on Humeral IMT Assessed by Vascular Echography
Time frame: 18 months
Secondary
Efficacy of Minoxidil on Supravalvular Stenosis, Pulmonary Stenosis, Aortic Stenosis and Renal Stenosis (Cardiac and Renal Echodoppler at J0, and M12)
Time frame: 12 months
Secondary
Genetic Study: Characterization of Deletions Responsible for WBS (Size Deletion, DNA Sample at Inclusion).
Time frame: Day 0